Back to top
more

Viking Therapeutics (VKTX)

(Delayed Data from NSDQ)

$25.40 USD

25.40
7,272,985

-0.64 (-2.46%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $25.64 +0.24 (0.94%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Ahan Chakraborty headshot

Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

by Ahan Chakraborty

NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.

Kinjel Shah headshot

Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?

by Kinjel Shah

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.

Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $33.69, moving +0.78% from the previous trading session.

Sundeep Ganoria headshot

Viking Therapeutics Stock Before Q4 Earnings: To Buy or Not to Buy?

by Sundeep Ganoria

Since VKTX is devoid of marketed drugs, investors will focus on pipeline updates when it reports Q4 results next week.

Ahan Chakraborty headshot

How to Play NVO Stock After New Drug's Success in Obesity Study

by Ahan Chakraborty

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh in on the stock's growth prospects.

Ahan Chakraborty headshot

GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise

by Ahan Chakraborty

Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.

Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.87, denoting a +0.67% change from the preceding trading day.

Zacks Equity Research

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Sundeep Ganoria headshot

NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down

by Sundeep Ganoria

Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales growth of its tirzepatide products in Q4.

Zacks Equity Research

LLY Stock Down on Lower-Than-Expected Sales Guidance for Q4

by Zacks Equity Research

LLY's shares slip more than 6% as it cuts outlook for 2024 sales. Preliminary fourth-quarter revenues fall short of estimates.

Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $38.88, marking a -1.09% move from the previous day.

Kinjel Shah headshot

LLY Falls Around 14% in 3 Months: How to Play the Stock

by Kinjel Shah

Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.

Zacks Equity Research

Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug

by Zacks Equity Research

The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.

Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $42.53, marking a -0.84% move from the previous day.

Zacks Equity Research

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Sundeep Ganoria headshot

VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?

by Sundeep Ganoria

Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.

Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $40.25, indicating a +1.19% shift from the previous trading day.

Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $42.68, representing a +0.78% change from its previous close.

Ahan Chakraborty headshot

Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?

by Ahan Chakraborty

NVO stock declines after a recent obesity study setback and intense competition from market rivals but offers long-term growth potential.

Zacks Equity Research

Lilly's Zepbound Receives FDA Approval for Sleep Apnea

by Zacks Equity Research

FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.

Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $42.25, marking a +1.83% move from the previous day.

Zacks Equity Research

Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug

by Zacks Equity Research

Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.

Zacks Equity Research

Here's Why VKTX Stock Plummeted 18% on Wednesday

by Zacks Equity Research

The selloff in Viking Therapeutics stock comes after some investors raised concerns for the small biotech amid Merck's entry into the obesity space.

Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) Stock Moves -1.75%: What You Should Know

by Zacks Equity Research

Viking Therapeutics, Inc. (VKTX) closed at $47.03 in the latest trading session, marking a -1.75% move from the prior day.